CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals (VRTX - Get Report) is pairing up with Johnson & Johnson (JNJ - Get Report) and GlaxoSmithKline (GSK - Get Report) in separate collaborations that will study new all-oral combination therapies for hepatitis C, the companies said Thursday.
Both new collaborations involve Vertex's nucleotide "nuc" polymerase inhibitor VX-135, formerly known as ALS-2200.
VX-135 will be combined with J&J's protease inhibitor simeprevir with and without ribavirin for 12 weeks in treatment-naive, genotype 1 hepatitis C patients. The phase II study is expected to begin in early 2013.In a separate phase II study, VX-135 will be combined with Glaxo's NS5A inhibitor GSK2336805 with and without ribavirin for 12 weeks in the same type of hepatitis C patients. Vertex, J&J and Glaxo will pay the costs of the new trials equally by and the collaborations do not involve any up-front or milestone payments. "We think is a good move for Vertex and should help quell concerns from some investors that the company wanted to prioritize Incivek combo regimens," writes ISI Group analyst Mark Schoenebaum in an email to clients Thursday morning. Incivek is Vertex's currently approved hepatitis C drug but it must be taken three times a day in a combination regimen that includes the injected immune booster interferon. Adds Schoenebaum: "Recall, however, that there is very little data available for VRTX's nuc
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.